RANKL plays a critical role in the development of osteolytic metastasis in the bones.39 It is highly expressed in the osteolytic lesions associated with malignant tumors.40 Moreover, by blocking the RANKL signaling, osteolytic lesions have been successfully inhibited in several types of cancer, including multiple myeloma and prostate cancer.41, 42, 43 Given this, the present study evaluated the effect of miR‐660‐5p on RANKL in lung cancer cells using western blot assay. Here, TNFSF11 is linked to plasma cell myeloma.